Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21201583 | 0.81 | POLB (0.44) | POLBNPSR1TSHRKEAP1NFE2L2 | |
| SCHEMBL22672555 | 0.80 | — | — | |
| SCHEMBL23343606 | 0.78 | POLB (0.42) | POLBNPSR1TSHRPSMB1ADRA1D | |
| SCHEMBL21527211 | 0.78 | POLB (0.44) | POLBNPSR1TSHRPSMB1PSMB5 | |
| SCHEMBL21419954 | 0.75 | IDH1 (0.33) | POLBTSHRPSMB1PSMB5IDH1 | |
| SCHEMBL17540820 | 0.74 | POLB (0.54) | POLBNPSR1KEAP1NFE2L2MAPT | |
| SCHEMBL924028 | 0.70 | TSHR (0.54) | POLBNPSR1TSHRMAPTMEN1 | |
| SCHEMBL9609774 | 0.70 | ALDH1A1 (0.49) | POLBNPSR1PSMB1PSMB5NPC1 | |
| SCHEMBL20665412 | 0.69 | POLB (0.44) | POLBNPSR1TSHRKEAP1NFE2L2 | |
| SCHEMBL21169913 | 0.69 | PRMT5 (0.44) | POLBNPSR1KEAP1NFE2L2PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2020-11-19 | — | — | US | disclosed |
| US-20200199116-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2020-06-25 | — | — | US | disclosed |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2019-10-31 | — | — | US | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199116-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3726/4885NPSR1 400/4885TSHR 1247/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 4140/4885NPSR1 372/4885TSHR 1196/4885 |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3726/4885NPSR1 400/4885TSHR 1247/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3901/4885NPSR1 442/4885TSHR 1220/4885 |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3726/4885NPSR1 400/4885TSHR 1247/4885 |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | POLB 3726/4885NPSR1 400/4885TSHR 1247/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3901/4885NPSR1 442/4885TSHR 1220/4885 |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3726/4885NPSR1 400/4885TSHR 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.